- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07933042
A Study of Urine Volatile Organic Compounds for Disease Detection (TOBY ATLAS)
TOBY ATLAS: A Multi-Site, Non-Interventional Study of Urinary Volatile Organic Compounds
The goal of this observational study is to develop and evaluate urine tests for detecting disease in adults. It will initially focus on prostate, bladder, and kidney cancer. Researchers will compare urine samples and medical records from people with and without these diseases to see whether the tests can detect them accurately. Participants may provide a urine sample during a routine visit. Study results will not be returned to participants or used in their care.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
TOBY ATLAS is a multi-center master protocol that supports the development and validation of urine-based tests for screening, diagnosis, and monitoring of multiple diseases. The study uses prospectively collected, residual, banked, and purchased urine samples, where permitted.
Researchers will analyze urine for volatile organic compounds using gas chromatography-mass spectrometry and develop models using samples with known disease status. Each model will be locked before it is evaluated using a separate set of blinded samples.
Disease status and available standard-of-care test results will be obtained from medical records. Researchers may also review records over time to identify later diagnoses or outcomes. Sites and diseases may be added as the study progresses.
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: TOBY ATLAS Study Team
- Telefonnummer: 309-592-8898
- E-post: info@toby.health
Studera Kontakt Backup
- Namn: TOBY ATLAS Study Team
- E-post: press@toby.health
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Adults with target diseases and comparison participants, including healthy volunteers and individuals with other diseases, benign conditions, or negative diagnostic work-ups. Participants are identified through routine care and other permitted specimen sources.
Beskrivning
Inclusion Criteria:
- Age 50 years or older, or another age range set in the applicable disease specification (for example, 45 or older for colorectal cancer).
- Informed consent, or eligibility under an exemption or waiver for waste, residual, banked, or purchased specimens.
- Medical records available for the reference standard.
- Meets the case or control definition and other inclusion criteria in at least one disease specification, or belongs to the Healthy Control Set.
Exclusion Criteria:
- Any exclusion stated in the applicable disease specification.
- Symptomatic urinary tract infection at collection, unless enrolled as a confounder control.
- Current pregnancy, imprisonment, or inability to consent for oneself (consented route).
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: CASE_CONTROL
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Target disease cases
Participants with a target disease established by the applicable reference standard, including participants assessed after treatment where specified. |
|
Controls
Participants without the target disease for a given analysis, including healthy participants and participants with other diseases, benign conditions, or negative diagnostic work-ups. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Clinical performance of each locked assay
Tidsram: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
Sensitivity and specificity at pre-specified thresholds, and area under the receiver operating characteristic curve, of each locked assay against the applicable reference standard in its intended-use population, using blinded validation specimens not used to develop that assay. Estimates will include 95% confidence intervals. |
At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
|
Paired comparison with available standard-of-care tests
Tidsram: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
Differences in sensitivity, specificity, and area under the receiver operating characteristic curve between each locked assay and each available standard-of-care test in the same participants, with 95% confidence intervals. |
At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Assay performance by subgroup and signal origin
Tidsram: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
Sensitivity, specificity, and area under the receiver operating characteristic curve across thresholds and by disease characteristics, populations, and control types, including stage, grade, and age; accuracy of signal-origin classification. |
At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
|
Protocol-conforming specimens with final reference-standard classification
Tidsram: From specimen collection through reference-standard classification, including medical-record review at approximately 12 months where available.
|
Number of protocol-conforming urine specimens with final reference-standard classification, summarized by disease and control type. |
From specimen collection through reference-standard classification, including medical-record review at approximately 12 months where available.
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Candidate assays advanced to validation
Tidsram: From study start through study completion, estimated up to 5 years
|
Number of candidate assays developed using the Development Pool that are locked and carried forward to a Validation Plan. |
From study start through study completion, estimated up to 5 years
|
|
Exploratory prognostic and simulated clinical and economic outcomes
Tidsram: Up to 5 years after specimen collection, where follow-up is permitted and available
|
Where optional medical-record follow-up is available, compare progression, recurrence, treatment response, stage at diagnosis, procedures, health care use, and costs with blinded assay predictions. These are exploratory prognostic and simulated health-economic analyses; test results are not used in care. |
Up to 5 years after specimen collection, where follow-up is permitted and available
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- TOBY-ATLAS-001
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
There is currently no plan to make individual participant data available to other researchers.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .